Table 2.
Results from case detection, verification, and subtyping tests depending on patient's outcome with adenoma or BAH
| Adenoma(n=11) | BAH(n=17) | P Value | |
|---|---|---|---|
| Morning serum aldosterone, pmol/L | 1197±611 | 874±587 | .15 |
| 24hU‐aldosterone concentration, μg/L | 44±17 | 34±12 | .01 |
| DRC, ng/L after 15 min of sitting | 3.3±2.3 | 9.6±8.1 | .008 |
| DRC, ng/L after 10 h of bed rest | 1.1±1.3 | 3.1±4.0 | <.001 |
| ARR, pmol/nga | 547±588 | 228±305 | 0.12 |
| Serum aldosterone, pmol/L, after IV salt loading for 4 h | 572±490 | 286±240 | .08 |
| Responsive to posture, No. | 4/10 | 13/16 | – |
| CT scan positive for nodule, No. | 8/11 | 3/17 | – |
| LI index after AVS | 16±14 | 1.6±0.5 | .009 |
Abbreviations: ARR, aldosterone/renin ratio; AVS, adrenal venous sampling; CT, computed tomography; DRC, direct renin concentration; BAH, bilateral adrenal hyperplasia; IV, intravenous; LI, lateralization index; 24hU‐aldosterone; 24‐hour urinary aldosterone.
a
Recommended cutoff according to current guidelines from the Endocrine Society is 144 pmol/ng.14